|
**Overview**: Creatinine Panel**Introduction**: The Creatinine Panel is a diagnostic tool designed to assess kidney function using serum and urine samples. In India, chronic kidney disease (CKD) affects ~17 percent of adults (higher in diabetes/hypertension patients), with creatinine and eGFR key for staging (eGFR <60 mL/min/1.73m² indicates CKD). BUN/creatinine ratio helps differentiate pre-renal from renal causes. High morbidity from underdiagnosis in rural/low-SES populations, limited nephrology access, delayed ACEi/statins/dialysis leading to end-stage renal disease. Per nephrology practices aligned with ICMR and Indian Society of Nephrology guidelines, the test employs spectrophotometry for creatinine, eGFR calculation, and ratio over 1-2 days with high accuracy, valuable for routine screening and monitoring. This diagnostic falls under kidney function screening and targets patients with diabetes, hypertension, or edema, addressing accurate detection to guide renoprotection. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing progression. Its serum/urine-based approach ensures reliable performance.**Other Names**: Creatinine Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: eGFR standardized; in India, key in diabetes screening programs.**Purpose**: The test assesses 3 parameters including creatinine and eGFR to guide kidney function evaluation, stage CKD, inform management.**Test Parameters**: 1. Creatinine, 2. eGFR, 3. BUN/Creatinine Ratio.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report edema, fatigue, or risk factors.**Specimen**: 3 mL serum in 1 SST and urine in sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on urine output, swelling, diabetes, hypertension, medications.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated kidney impairment including dialysis need, benefits of early detection, and minimal discomfort from blood/urine collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or muscle mass/diet can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated creatinine/low eGFR indicates kidney impairment, necessitating specialist input. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: Nephrologists should be consulted for management.**Additional Supporting Tests**: Urine albumin/creatinine ratio, ultrasound for confirmation.**Test Limitations**: Creatinine influenced by muscle mass; comprehensive approach required.**References**: Indian Journal of Nephrology 2024, CKD Studies India 2023. |
